• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $INDP

    Indaptus Therapeutics Inc.

    Subscribe to $INDP
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics, Inc., a pre-clinical stage biotech company, develops a patented anti-cancer and antiviral immunotherapy. It engages in developing a pre-clinical pipeline of therapeutic candidates intended to elicit anti-tumor and anti-viral responses, as well as cure diseases. The company's lead candidate is Decoy20 that is in pre-clinical stage to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. It also develops a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company is headquartered in New York, New York.

    IPO Year:

    Exchange: NASDAQ

    Website: indaptusrx.com

    Recent Analyst Ratings for Indaptus Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    1/31/2022$15.00Buy
    HC Wainwright & Co.
    10/19/2021$16.00Hold → Buy
    Maxim Group
    See more ratings

    Indaptus Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Karah Hila

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      6/11/25 4:05:18 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Martell Robert

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      6/11/25 4:05:17 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Pomerantz Roger

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      6/11/25 4:05:13 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hayes William B

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      6/11/25 4:05:15 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Maddaluna Anthony J

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      6/11/25 4:05:14 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gilbert Mark John

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      6/11/25 4:05:11 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Director Meckler Jeffrey A was granted 42,553 shares, increasing direct ownership by 27% to 202,859 units (SEC Form 4)

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      11/26/24 4:12:39 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and Director Meckler Jeffrey A

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      10/10/24 4:05:09 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Linscott Walt Addison

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      10/10/24 4:05:10 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CSO and Director Newman Michael James

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      10/10/24 4:05:15 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Indaptus Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. resumed coverage on Indaptus Therapeutics with a new price target

      HC Wainwright & Co. resumed coverage of Indaptus Therapeutics with a rating of Buy and set a new price target of $15.00

      1/31/22 7:21:10 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics upgraded by Maxim Group with a new price target

      Maxim Group upgraded Indaptus Therapeutics from Hold to Buy and set a new price target of $16.00

      10/19/21 8:57:59 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care